Oncology Terminology Simplified: Communicate with Confidence

Conversations about cancer can be some of the most challenging in veterinary medicine. Veterinary professionals are tasked with striking a delicate balance between a highly emotional topic that should be handled with compassion and helping clients navigate advanced terminology.

Words like cytology, histopathology, metastasis, and remission are routine for clinicians but can feel intimidating or confusing to clients and even to newer team members. Mastering oncology terminology is not just academic—it’s essential for clear communication, building trust, and guiding care decisions.

Let's break down standard oncology terms, explain when and how to translate them into everyday language, and highlight the importance of consistency across the veterinary team.

Cytology, Histopathology, and Staging

Cytology, histopathology, and staging tests each play distinct roles in the identification and management of cancer, and explaining their differences helps pet owners appreciate why veterinarians may need to perform multiple steps or tests. Let's explore:

Test

What it is

Strengths

Limitations

Cytology

Microscopic evaluation of cells obtained through techniques such as fine needle aspirate, swab, etc.

Quick, minimally invasive, often performed in-house

May not identify a definitive subtype, not generally recommended to determine grade

Histopathology

Microscopic evaluation of tissue architecture from a piece of tissue (biopsy)

Greater context: See the forest, not only trees.

Requires sedation or anesthesia, longer turnaround

Grading

Assessing microscopic tumor features such as mitotic count, invasion, necrosis, etc. and assigning a tumor to a category based on these features   

Predicts how aggressive a tumor is likely to be, guides prognosis and treatment options

Requires histopathology samples, can vary in different areas of a tumor so small samples may not represent the whole

Staging

Imaging and sampling to look for cancer spread

Defines extent of disease, guides prognosis and treatment options

Cost and logistics, may require referral

It can be challenging to convey this information to clients in a straightforward, simple way. A potential way to frame this for clients is with clear language.

For example: “Cytology can sometimes show if an infection is present instead of cancer or may confirm cancer without needing more invasive procedures thus saving time, cost and risk. A biopsy usually tells us what type of cancer it is and how it might behave. Once we know the type, staging helps predict the outlook and decide on the best treatment plan."

Treatment Intent and Modalities

Treatment discussions hinge on intent: curative versus palliative. Another distinction in treatment is between local and systemic therapies. The former targets the tumor directly and includes surgery and radiation. And the latter targets cancer throughout the body and includes chemotherapy.

Clients benefit from clear definitions early in the conversation.

Intent

Definition

Examples

Curative

Aim to eliminate disease

  • Surgery alone for low-grade, low-stage tumors

  • Surgery and radiation for local control

  • Surgery and chemotherapy for aggressive tumors that are likely to spread

Palliative

Aim to reduce clinical signs and improve comfort

  • Radiation to reduce discomfort associated with nasal tumors that surgery can’t treat

  • Amputation alone to relieve pain due to osteosarcoma

  • Chemotherapy for mast cell tumors that are too large to remove with surgery

Chemotherapy Approaches for Pets

Veterinary teams use several chemotherapy approaches to treat cancer in pets. Below, we'll explore the differences between maximum tolerated dose chemotherapy, metronomic chemotherapy, and targeted therapies.

Maximum Tolerated Dose Chemotherapy

Maximum tolerated dose (MTD) chemotherapy is the most common approach to treating cancer, and uses high, intermittent doses to kill as many tumor cells as possible. Because rapidly dividing cells are targeted, we see predictable side effects, such as decreased white blood cells and gastrointestinal upset.

Metronomic Chemotherapy

Metronomic chemotherapy uses low doses, often daily. The aim is to slow tumor growth, but may not caisee a tumor to shrink. The treatment has minimal short-term side effects.

Targeted Therapies

Targeted therapies, such as toceranib (Palladia), block specific pathways in tumor growth and spread. Few are approved for use in animals, but many treatments used in people are also effective for dogs and cats. These have side effects that may be similar to traditional chemotherapy drugs (low white blood cells and gastrointestinal), or completely different, like hypertension and protein loss through the kidneys. Knowing the potential side effects of these treatments is essential to prepare owners for what to look out for in their pet.

Explaining Remission, Recurrence, and Metastasis

When discussing treatment goals and outcomes, remission is best explained as "the cancer shrinking or disappearing." Veterinarians should clarify that complete remission means no measurable tumor remains, whereas partial remission means the tumor has shrunk but remains measurable.

Stable disease is another term for when a tumor isn’t shrinking but isn’t significantly increasing in size. Progressive disease means that the cancer is getting worse by either growing where it started or spreading throughout the body. While complete remission may be the goal, partial remission and stable disease may be acceptable as long as the pet feels good and has a satisfactory quality of life.

Term

Meaning

Client-friendly phrasing

Complete remission

No measurable tumor remains

“We can’t see or measure the cancer right now, but we’ll continue to monitor.”

Partial remission

Tumor has shrunk significantly

“It’s smaller and responding to treatment, but isn't entirely gone.”

Stable disease

No significant growth or shrinkage

“It hasn’t changed much with treatment. It’s holding steady.”

Progressive disease

Tumor is worsening or spreading

“It’s growing despite treatment, so we need to adjust our plan.”

You can explain recurrence or relapse as “the cancer coming back after or during treatment,” and metastasis as “the cancer traveling to other parts of the body.” These translations also help owners understand the importance of staging tests and continuous monitoring throughout treatment.

By clearly explaining these definitions up front, you can help a client understand what success looks like for their pet and the specific treatments that you recommend.

Building Your Team's Oncology Vocabulary

Consistency across the veterinary team is critical. When clinicians, technicians, and support staff use the same definitions and explanations, clients receive direct, unified messaging. This reduces confusion, builds trust, and ensures smoother case management. Practical steps include:

  • Standardize the words used in your records and discharges
  • Develop scripts for common talking points (e.g., “Grade tells us how scary a cancer might be; and stage tells us how far it is behaving”)
  • Train new team members to pair technical terms with plain-language translations

Clear Communication Leads to Better Care and Patient Outcomes

Oncology terminology is more than just medical jargon—it’s the foundation of communication. By mastering the language of cancer, veterinarians and technicians can translate complex concepts into everyday language, set realistic expectations, and build stronger relationships with clients. A shared vocabulary within the team ensures consistency, clarity, and confidence in every cancer conversation.

Clear communication doesn't stand alone. It works alongside diagnostics, treatment plans, and clinical expertise. In oncology cases, where decisions can be complex and emotional, shared language helps teams stay aligned and helps clients feel informed and supported.

 

 

 

 

 

 

 

Christopher Fulkerson
DVM, MS, DACVIM (Oncology)

Dr. Fulkerson is a Board-Certified Veterinary Oncologist and faculty member at Purdue University. He attended Purdue University for veterinary school and Texas A&M for a Rotating Internship, then returned for a Residency. He is a member of the Purdue Institute for Cancer Research and the Evan and Sue Ann Werling Comparative Oncology Center, and active volunteer for the ACVIM. His research focuses on drug discovery, canine clinical trials, and caregiver burden and its sequelae for pet owners and the veterinary team. He advocates for well-being in the veterinary profession, and particularly trainees. The views and opinions in this piece are the author's own and do not necessarily reflect the views of either The Vetiverse or IDEXX.


Don’t just keep up. Stay ahead. Sign up for the IDEXX Education Newsletter.